Navigation Links
Inovio Pharmaceuticals Cytomegalovirus (CMV) Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study
Date:11/26/2012

achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, our ability to secure new partnerships and collaborations, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2011, our Form 10-Q for the quarter ended September 30, 2012, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

(Logo: http://photos.prnewswire.com/prnh
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
2. Inovio Pharmaceuticals to Present at Noble Financial 8th Annual Equity Conference
3. Inovios Scientific Advisory Board Chairman Elected as a Fellow by the American Association for the Advancement of Science
4. Inovio Pharmaceuticals to Present at Noble Financial Life Sciences Conference
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
6. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
7. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
8. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
9. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
10. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
11. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... (PRWEB) January 15, 2014 More than ... and about 1 in 3 seniors will die with ... ). These jaw-dropping figures have shocked many Americans into ... hopefully, help prevent these tragic age-related cognitive disorders. Jonathan ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... throughput research solutions, today announced that Lupin Limited, one ... of Freeslate’s CM Protégé PharmD System for ... in Mumbai, India, is focused on a wide range ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo ... institutes from the National Institutes of Health (NIH) to ... more effective treatments to patients on a faster timeline. ... Translational Sciences (NCATS) and the National Eye Institute (NEI) ...
Breaking Biology Technology:Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
... 26 Bionovo, Inc.,(Nasdaq: BNVI ) (the "Company") today ... of common stock at a price to the public of,$2.50 ... stock,at $3.50 per share at a price of $0.10 per ... to purchase up to an additional 15% of,the offering to ...
... - International Call for Patient Group Task ... international research, including the views of bodies that,represent ... today in,Dublin, Ireland - one of the world,s ... campaigner has called for patient,groups across Europe to ...
... Sunesis,Pharmaceuticals, Inc. (Nasdaq: SNSS ), a ... that,management will hold an investor conference call on ... PT to discuss financial results for the,third quarter ... the call via (888),297-0358 (U.S. and Canada) or ...
Cached Biology Technology:Bionovo Announces the Pricing of Public Offering of Shares of Common Stock 2Bionovo Announces the Pricing of Public Offering of Shares of Common Stock 3Patients Fail to Take Fake Medicines Risk Seriously 2Patients Fail to Take Fake Medicines Risk Seriously 3
(Date:4/17/2014)... new early-warning signs of the potential loss of sight ... for the diagnosis and treatment of diabetic retinopathy, potentially ... "We had not expected to see such striking changes ... Elsner, professor and associate dean in the IU School ... set out to study the early signs, in volunteer ...
(Date:4/17/2014)... wild animals and plant life, but there,s an invisible ... in the soil, decomposing organic matter and releasing carbon ... fungi play in ecological systems, their identities have only ... generated a genetic map of more than 10,000 species ... this week in the Proceedings of the National ...
(Date:4/17/2014)... View of Domestication," a special feature of The ... ( PNAS ) published April 29, raises a ... deep history that most of us take for granted. ... in many spots around the globe shifted from hunting ... and plants. , It seems so straightforward and yet ...
Breaking Biology News(10 mins):New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3Stanford biologists help solve fungal mysteries 2Stanford biologists help solve fungal mysteries 3Genetic study tackles mystery of slow plant domestications 2Genetic study tackles mystery of slow plant domestications 3Genetic study tackles mystery of slow plant domestications 4
... August 8th, 2011, Shenzhen, China BGI, the ... Shenzhen Second People,s Hospital, announced today that the study ... cell carcinoma (TCC) of the bladder was published online ... valuable genetic basis for future studies on TCC, suggesting ...
... WEST LAFAYETTE, Ind. -- A Purdue University scientist is urging ... allowed for U.S. consumption and arguing that not doing so ... William Muir, a professor of animal sciences, said that based ... Administration, AquAdvantage (AA) salmon poses little real risk to the ...
... is currently used as a component of intravenous nutrition and ... protection for patients suffering from heart attacks. Current ... of the ischemic period, when blood flow to tissues is ... blood flow. It is well known that injury to the ...
Cached Biology News:Research discovers frequent mutations of chromatin remodeling genes in TCC of the bladder 2Scientist urges government ruling on genetically engineered salmon 2Scientist urges government ruling on genetically engineered salmon 3
... Technology's family of light scattering instruments. The ... chromatograph and enables you to get multi-angle ... HTmD is easily installed in the oven ... 2000 device and enables you to get ...
...
... Experion HighSens reagents and supplies, for ... supplies sufficient to perform high-sensitivity RNA ... on the Experion automated electrophoresis system. ... 20 microliters RNA HighSens stain, 20 ...
MAb to Verotoxin II (SLT-2a) Verotoxin II (Shiga-like) A subunit (SLT-2a)...
Biology Products: